Informação sobre produto
- (3R,4R,5E,10E,12E,14S,26R,26aS)-26-[[2-(Diethylamino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a-octahydro-14-hydroxy-4,12-dimethyl-3-(1- methylethyl)-3H-21,18-nitrilo-1H,22H-pyrrolo[2,1-c][1,8,4,19]dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetrone(26R
- (3R,4R,5E,10E,12E,14S,26R,26aS)-26-((2-(Diethylamino)ethyl)sulfonyl)-8,9,14,15,24,25,26,26a-octahydro-14-hydroxy-3-isopropyl-4,12-dimethyl-3H-21,18-nitrilo-1H,22H-pyrrolo(2,1-c)(1,8,4,19)dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetrone
- (3R,4R,5E,10E,12E,14S,26R,26aS)-26-[[2-(Diethylamino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a-octahydro-14-hydroxy-4,12-dimethyl-3-(1-methylethyl)-3H-21,18-nitrilo-1H,22H-pyrrolo[2,1-c][1,8,4,19]dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetrone
- (3R,4R,5Z,10Z,12Z,14S,26R,26aS)-26-{[2-(diethylamino)ethyl]sulfonyl}-14-hydroxy-4,12-dimethyl-3-(1-methylethyl)-8,9,14,15,24,25,26,26a-octahydro-1H,3H,22H-21,18-(azeno)pyrrolo[2,1-c][1,8,4,19]dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetrone
- 3H-21,18-Nitrilo-1H,22H-pyrrolo[2,1-c][1,8,4,19]dioxadiazacyclotetracosine, virginiamycin M<sub>1</sub> deriv.
- 3H-21,18-Nitrilo-1H,22H-pyrrolo[2,1-c][1,8,4,19]dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetrone, 26-[[2-(diethylamino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a-octahydro-14-hydroxy-4,12-dimethyl-3-(1-methylethyl)-, (3R,4R,5E,10E,12E,14S,26R,26aS)-
- Dalfopristin [USAN:INN]
- Dalfopristina
- Dalfopristina [INN-Spanish]
- Dalfopristine
- Ver mais sinónimos
- Dalfopristine [INN-French]
- Dalfopristinum
- Dalfopristinum [INN-Latin]
- Rp 54476
- Unii-R9M4Fje48E
- Virginiamycin M1, 26-((2-(diethylamino)ethyl)sulfonyl)-26,27-dihydro-, (26R,27S)-
- Virginiamycin M<sub>1</sub>, 26-[[2-(diethylamino)ethyl]sulfonyl]-26,27-dihydro-, (26R,27S)-
- 3H-21,18-Nitrilo-1H,22H-pyrrolo[2,1-c][1,8,4,19]dioxadiazacyclotetracosine, virginiamycin M1 deriv.
Dalfopristin is an antimicrobial agent that inhibits the growth of bacteria by blocking protein synthesis. It is a combination drug consisting of dalfopristin and quinupristin, which are active against Gram-positive bacteria but not against Gram-negative bacteria. The mechanism of action of dalfopristin is similar to erythromycin, but it has a broader spectrum of activity against resistant mutants. Dalfopristin has been used as a treatment for MRSA infections and in the prevention of postoperative infections after surgical procedures. Dalfopristin is also used in combination with other antibiotics for the treatment of various bacterial infections.